Evidence map›Paper›PMID 25630406›Full record

ArticleClinical and vaccine immunology : CVI2015

Protective immunogenicity of group A streptococcal M-related proteins.

James B Dale, Shannon E Niedermeyer, Tina Agbaosi, Nicholas D Hysmith, Thomas A Penfound, Claudia M Hohn, Matthew Pullen, Michael I Bright, Daniel S Murrell, Lori E Shenep and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. The virulence factors of group A streptococcus strains isolated from invasive and non-invasive infections in Polish and German centres, 2009-2011.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2017
    Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

James B DaleDepartment of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA Department of Microbiology, Immunology and Biochemistry, Memphis, Tennessee, USA Department of Veterans Affairs Medical Center, Memphis, Tennessee, USA jbdale@uthsc.edu.
Shannon E NiedermeyerDepartment of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA Department of Veterans Affairs Medical Center, Memphis, Tennessee, USA.
Tina AgbaosiDepartment of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA Department of Veterans Affairs Medical Center, Memphis, Tennessee, USA.
Nicholas D HysmithDepartment of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA Department of Veterans Affairs Medical Center, Memphis, Tennessee, USA St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Thomas A PenfoundDepartment of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA Department of Veterans Affairs Medical Center, Memphis, Tennessee, USA.
Claudia M HohnDepartment of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA Department of Veterans Affairs Medical Center, Memphis, Tennessee, USA.
Matthew PullenDepartment of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA Department of Veterans Affairs Medical Center, Memphis, Tennessee, USA.
Michael I BrightDepartment of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA Department of Veterans Affairs Medical Center, Memphis, Tennessee, USA.
Daniel S MurrellDepartment of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA Department of Veterans Affairs Medical Center, Memphis, Tennessee, USA.
Lori E ShenepDepartment of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA Department of Veterans Affairs Medical Center, Memphis, Tennessee, USA.
Harry S CourtneyDepartment of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA Department of Veterans Affairs Medical Center, Memphis, Tennessee, USA.
University of Tennessee Health Science Center · USSt. Jude Children's Research Hospital · US

Funding

Chemistry and Immunology of Streptococcal M ProteinsR37AI010085 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI DALE, JAMES B. · 1986 to 2010
$3.3M
Vaccine Prevention of Group A Streptococcal InfectionsR01AI010085 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI DALE, JAMES B. · 1985 to 2016
$2.4M
Short-Term Research Training for Medical StudentsT35DK007405 · NIDDK · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI SOLOMON, SOLOMON SIDNEY · 1990 to 2014
$1.8M
LEPIDOPTERAN B THURINGIENSIS TOXIN RF32AI009582 · NIAID · UNIVERSITY OF WYOMING · PI KEETON, TIMOTHY P · 1996 to 1997
–
CHEMISTRY AND IMMUNOLOGY OF STREPTOCOCCAL M PROTEINSR55AI010085 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI DALE, JAMES B. · 1991 to 1991
–
NIAID NIH HHS AI-09582NIAID NIH HHS AI-10085NIAID NIH HHS F32 AI009582NIAID NIH HHS R01 AI010085NIAID NIH HHS R37 AI010085NIDDK NIH HHS T35 DK007405NIDDK NIH HHS T35DK-007405
6 · The paper itself

Abstract

Many previous studies have focused on the surface M proteins of group A streptococci (GAS) as virulence determinants and protective antigens. However, the majority of GAS isolates express M-related protein (Mrp) in addition to M protein, and both have been shown to be required for optimal virulence. In the current study, we evaluated the protective immunogenicity of Mrp to determine its potential as a vaccine component that may broaden the coverage of M protein-based vaccines. Sequence analyses of 33 mrp genes indicated that there are three families of structurally related Mrps (MrpI, MrpII, and MrpIII). N-terminal peptides of Mrps were cloned, expressed, and purified from M type 2 (M2) (MrpI), M4 (MrpII), and M49 (MrpIII) GAS. Rabbit antisera against the Mrps reacted at high titers with the homologous Mrp, as determined by enzyme-linked immunosorbent assay, and promoted bactericidal activity against GAS emm types expressing Mrps within the same family. Mice passively immunized with rabbit antisera against MrpII were protected against challenge infections with M28 GAS. Assays for Mrp antibodies in serum samples from 281 pediatric subjects aged 2 to 16 indicated that the Mrp immune response correlated with increasing age of the subjects. Affinity-purified human Mrp antibodies promoted bactericidal activity against a number of GAS representing different emm types that expressed an Mrp within the same family but showed no activity against emm types expressing an Mrp from a different family. Our results indicate that Mrps have semiconserved N-terminal sequences that contain bactericidal epitopes which are immunogenic in humans. These findings may have direct implications for the development of GAS vaccines.

Indexed as

AdolescentAge FactorsAmino Acid SequenceAnimalsAntibodies, BacterialAntigens, BacterialBacterial Outer Membrane ProteinsChildChild, PreschoolEnzyme-Linked Immunosorbent AssayFemaleHumansImmune SeraImmunization, PassiveMaleMiceAntibodies, BacterialAntigens, BacterialBacterial Outer Membrane ProteinsImmune SeraRecombinant Proteins

Identifiers

PMID25630406
PMCPMC4340887
OpenAlexW2150286888

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.